Talaris Therapeutics Valuation
| TALSDelisted Stock | USD 2.98 0.10 3.25% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Talaris Therapeutics has a current Real Value of $2.42 per share. The regular price of the company is $2.98. Our model measures the value of Talaris Therapeutics from inspecting the company fundamentals such as Return On Equity of -0.42, shares outstanding of 42.81 M, and Shares Owned By Institutions of 77.67 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Talaris Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Talaris Therapeutics is based on 3 months time horizon. Increasing Talaris Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Talaris stock is determined by what a typical buyer is willing to pay for full or partial control of Talaris Therapeutics. Since Talaris Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Talaris Stock. However, Talaris Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.98 | Real 2.42 | Hype 2.98 |
The intrinsic value of Talaris Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Talaris Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Talaris Therapeutics helps investors to forecast how Talaris stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Talaris Therapeutics more accurately as focusing exclusively on Talaris Therapeutics' fundamentals will not take into account other important factors: Talaris Therapeutics Total Value Analysis
Talaris Therapeutics is at this time expected to have valuation of (28.92 M) with market capitalization of 125.73 M, debt of 2.88 M, and cash on hands of 207.11 M. The negative valuation of Talaris Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Talaris Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(28.92 M) | 125.73 M | 2.88 M | 207.11 M |
Talaris Therapeutics Asset Utilization
One of the ways to look at asset utilization of Talaris is to check how much profit was generated for every dollar of assets it reports. Talaris Therapeutics has a negative utilization of assets of -0.23 %, losing $0.002281 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Talaris Therapeutics shows how discouraging it operates for each dollar spent on its assets.Talaris Therapeutics Ownership Allocation
Talaris Therapeutics shows a total of 42.81 Million outstanding shares. The majority of Talaris Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Talaris Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Talaris Therapeutics. Please pay attention to any change in the institutional holdings of Talaris Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Talaris Therapeutics Profitability Analysis
Net Loss for the year was (73.89 M) with profit before overhead, payroll, taxes, and interest of 0.About Talaris Therapeutics Valuation
The delisted stock valuation mechanism determines Talaris Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Talaris Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Talaris Therapeutics. We calculate exposure to Talaris Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Talaris Therapeutics's related companies.Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky. Talaris Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 128 people.
Talaris Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Talaris Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 41.2 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Other Consideration for investing in Talaris Stock
If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |